Stop & Shop announces reorganization
QUINCY, Mass. A corporate reorganization is in the works for a Royal Ahold subsidiary, and it could spell job losses at the chain’s headquarters.
Stop & Shop announced Wednesday a new retail merchandising and marketing structure but would not elaborate on details of the reorganization, according to published reports. Stop & Shop, which is headquarted in Quincy, Mass., may scale back its workforce, possibly moving employees and/or operations of nonperishable and fresh merchandising functions to Carlisle, Pa., where Royal Ahold’s Ahold USA Retail offices are located.
According to spokeswoman Faith Weiner, Stop & Shop will remain one of the state’s biggest employers, with more than 20,000 workers in Massachusetts. Stop & Shop employed more than 800 people at its Quincy headquarters as of five years ago, according to The Patriot Ledger.
FMI praises Brown’s Super Markets president’s commitment to consumers
ARLINGTON, Va. An organization representing food retailers and wholesalers praised one grocery chain head’s commitment to improving the availability of nutritious food for its consumers.
The Food Marketing Institute that testimony presented before the House Agriculture Subcommittee on Department Operations, Oversight, Nutrition, and Forestry by Jeff Brown, president and owner of Brown’s Super Markets, shows how partnerships with federal and community leaders “can overcome the challenges inherent in building stores in underserved areas.”
“Food Marketing Institute applauds Jeff Brown for sharing his vision and success in bringing fresh, affordable and nutritious food to low-income Americans in areas that lack ready access to supermarkets, said Leslie Sarasin, FMI president and CEO. “Retail food stores are the cornerstone of communities nationwide, creating numerous jobs and serving as catalyst for economic growth.”
Pfizer Oncology to present cancer drugs at annual cancer research conference
NEW YORK Presenters from Pfizer’s cancer drugs unit will have a lot of work to do at the annual meeting of the American Association for Cancer Research in Washington this weekend.
Pfizer Oncology announced Wednesday that the company would present data on investigational cancer drugs such as figitumumab, a monoclonal antibody for lung cancer, as well as Sutent (sunitinib) and the kidney cancer drug axitinib, as well as drugs for lymphoma and others.
“Pfizer’s data at AACR demonstrate our strategic focus on the discovery and development of novel mechanisms that align complex biology with creative clinical strategies,” Pfizer Oncology Research Unit chief scientific officer Neil Gibson said. “Our research on the mutations and pathways that are genetic drivers of the segments of disease, defined by specific ‘genetic signatures,’ is designed to help us identify patient populations that will derive the most benefit from the novel therapeutic modalities we discover and develop.”